About
Hannah Bolland is a Surrey Future Fellow at the University of Surrey, School of Veterinary Medicine, Faculty of Health and Medical Sciences. She holds a PhD from the University of Nottingham (investigating RNA helicases in hypoxic colorectal cancers) and completed postdoctoral research at the University of Oxford’s Institute of Radiation Oncology, focusing on radiosensitization mechanisms in hypoxic cells. Her research explores peroxisome biogenesis in cancers, tumor microenvironment dynamics, and hypoxia-driven therapy resistance. She is also a Fellow of Advance HE (FHEA).
- Education:
- PhD in Cancer Biology, University of Nottingham
- Postdoctoral Research, University of Oxford
Research Interests: Her work spans hypoxia-induced therapy resistance, peroxisome roles in cancer metabolism, reactive oxygen species (ROS), and tumor microenvironment modulation. She investigates novel chemical biology tools for hypoxia measurement and develops strategies to enhance radiotherapy efficacy via targeting metabolic pathways.
Publications: Her recent work includes hypoxia-activated fluorescent probes, radiosensitizing Polθ inhibitors, and bioreductive drug delivery systems. These studies highlight advancements in cancer diagnostics and therapeutic strategies.
- Awards: Surrey Future Fellow, Fellow of Advance HE
Grants & Advising: While specific grants are not detailed, her research aligns with translational oncology priorities. Collaborations include work on CREBBP bromodomain ligands and hypoxia-activated prodrugs.
